Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 113

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 2
Chunk 113
---
 prior to the consummation of the initial business combination, including interest (net of funds withdrawn
to pay our taxes, if any), divided by the number of then issued and outstanding public shares, subject to certain limitations. Our public
shareholders will be permitted to redeem their shares regardless of whether they abstain, vote for, vote against, or vote at all with
respect to the proposed business combination. There will be no redemption rights upon the completion of our initial business combination
with respect to our rights. Our sponsor, directors and officers have entered into a letter agreement with us, pursuant to which they
have agreed to waive their redemption rights with respect to any shares held by them in connection with the completion of our initial
business combination.

If
a shareholder vote on our initial business combination is not required by law and we do not decide to hold a shareholder vote for business
or other legal reasons, we will offer to redeem our public shares pursuant to Rule 13e-4 and Regulation 14E under the Exchange Act, and
will file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same
financial and other information about our initial business combination and the redemption rights as is required under Regulation 14A
under the Exchange Act.

Results
of Operations

We
have neither engaged in any operations nor generated any revenues to date. Our only activities from May 23, 2024 (inception) through
September 30, 2025 were organizational activities, those necessary to prepare for the Initial Public Offering, described below, and subsequent
to the Initial Public Offering, identifying a target company for an initial business combination. We do not expect to generate any operating
revenues until after the completion of our initial business combination. We generate non-operating income in the form of interest earned
on cash and investments held in the trust account. We incur expenses as a result of being a public company (for legal, financial reporting,
accounting and auditing compliance), as well as for due diligence expenses.

For
the three months ended September 30, 2025, we had a net income of $2,184,563, which consists of interest earned on cash and investments
held in the trust account of $2,448,266, offset by general and administrative costs of $263,703.

For
the nine months ended September 30, 2025, we had a net income of $5,727,685, which consists of interest earned on cash